AU2066797A - Assays for kdr/flk-1 receptor tyrosine kinase inhibitors - Google Patents

Assays for kdr/flk-1 receptor tyrosine kinase inhibitors

Info

Publication number
AU2066797A
AU2066797A AU20667/97A AU2066797A AU2066797A AU 2066797 A AU2066797 A AU 2066797A AU 20667/97 A AU20667/97 A AU 20667/97A AU 2066797 A AU2066797 A AU 2066797A AU 2066797 A AU2066797 A AU 2066797A
Authority
AU
Australia
Prior art keywords
flk
kdr
assays
tyrosine kinase
kinase inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU20667/97A
Inventor
Klaus P. Hirth
Gerald Mcmahon
Laura K Shawver
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sugen LLC
Original Assignee
Sugen LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sugen LLC filed Critical Sugen LLC
Publication of AU2066797A publication Critical patent/AU2066797A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU20667/97A 1996-03-21 1997-03-04 Assays for kdr/flk-1 receptor tyrosine kinase inhibitors Abandoned AU2066797A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62173496A 1996-03-21 1996-03-21
US08621734 1996-03-21
PCT/US1997/003378 WO1997034920A1 (en) 1996-03-21 1997-03-04 Assays for kdr/flk-1 receptor tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
AU2066797A true AU2066797A (en) 1997-10-10

Family

ID=24491410

Family Applications (1)

Application Number Title Priority Date Filing Date
AU20667/97A Abandoned AU2066797A (en) 1996-03-21 1997-03-04 Assays for kdr/flk-1 receptor tyrosine kinase inhibitors

Country Status (2)

Country Link
AU (1) AU2066797A (en)
WO (1) WO1997034920A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
AU7622698A (en) * 1996-12-05 1998-06-29 Sugen, Inc. Use of indolinone compounds as modulators of protein kinases
AU3850299A (en) * 1998-05-20 1999-12-06 Kyowa Hakko Kogyo Co. Ltd. Vegf activity inhibitors
ATE321856T1 (en) * 1998-06-11 2006-04-15 HUMAN RECEPTOR TYROSINE KINASE
PT1105136E (en) * 1998-08-13 2007-12-03 Novartis Ag Method for treating ocular neovascular diseases
NZ511559A (en) * 1998-11-23 2004-01-30 Novartis Ag Use of staurosporine derivatives for treating ocular neovascular diseases
US6214819B1 (en) 1998-11-23 2001-04-10 Novartis Ag Method for treating ocular neovascular diseases
GB9918057D0 (en) * 1999-07-30 1999-10-06 Univ Bristol Therapeutic agents
US6271233B1 (en) 1999-08-10 2001-08-07 Ciba Vision Corporation Method for treating ocular neovascular diseases
MXPA02001439A (en) * 1999-08-11 2002-08-30 Eos Biotechnology Inc Novel methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators.
AU1347301A (en) * 1999-10-28 2001-05-08 Procter & Gamble Company, The The use of a complex of vegfr-2 and neuropilin-1 for identification of novel pro- and anti-angiogenic actives
BR0111530A (en) * 2000-06-07 2003-07-22 Ortho Mcneil Pharm Inc Process for detecting vegf kinase domain modulation
EP1311277A4 (en) * 2000-07-18 2004-08-25 Joslin Diabetes Center Inc Methods of modulating fibrosis
US6649367B2 (en) * 2001-03-22 2003-11-18 Eisai Co., Ltd Human cancer cell line malignantly altered by expression of angiogenic factor
US7268137B2 (en) * 2002-11-07 2007-09-11 Campochiaro Peter A Ocular therapy
US7771742B2 (en) 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
AU2011211380B9 (en) * 2004-04-30 2014-05-08 Allergan, Inc. Biodegradable intravitreal tyrosine kinase inhibitor implants
BRPI0510485A (en) 2004-04-30 2007-11-13 Allergan Inc biodegradable intravitreal tyrosine kinase inhibitor implants

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6177401B1 (en) * 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
US5840301A (en) * 1994-02-10 1998-11-24 Imclone Systems Incorporated Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors

Also Published As

Publication number Publication date
WO1997034920A1 (en) 1997-09-25

Similar Documents

Publication Publication Date Title
AU2066797A (en) Assays for kdr/flk-1 receptor tyrosine kinase inhibitors
HUS1700048I1 (en) Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
AU2396897A (en) 5-aminopyrazoles useful as selective inhibitors of the protein tyrosine kinase p56ick
AU3443997A (en) Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
AU3693697A (en) Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
AU6411698A (en) Substituted 2-anilinopyrimidines useful as protein kinase inhibitors
AU3766897A (en) Fused heterocyclic compounds as protein tyrosine kinase inhibitors
DE69622652D1 (en) Substituierte indolymethylen-oxindol-analoge als tyrosin kinase inhibitoren
AU4956297A (en) Raf kinase inhibitors
AU7289696A (en) Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
AU7631496A (en) Substituted 2-anilinopyrimidines useful as protein kinase inhibitors
AU2697897A (en) Indole derivatives useful as endothelin receptor antagonists
PL346934A1 (en) Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
AU6998000A (en) Substituted indolinones as tyrosine kinase inhibitors
ZA975380B (en) Bicyclic 4-aralkylaminopyrimidine derivatives as tyrosine kinase inhibitors.
AU6882598A (en) Protein kinase inhibitor
AU1518595A (en) Antagonists to insulin receptor tyrosine kinase inhibitor
AU3703499A (en) Substituted indolinones as kinase inhibitors
GB9611797D0 (en) Substituted quinolylmethylen-oxindole analogues as tyrosine kinase inhibitors
GB9610964D0 (en) Substituted tetralylmethylen-oxindole analogues as tyrosine kinase inhibitors
AU6569898A (en) Leukotriene antagonists useful for treating iritis
ZA945372B (en) Tyrosine kinase receptor
AU6770398A (en) Histidine kinase assay
AU2963395A (en) Mlk receptor tyrosine kinases
EP0800531A4 (en) Novel receptor tyrosine kinases